Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 7:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: melphalan Clear all
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Autologous Lymphocytes, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Not applicable Interventional

Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant

NCT01416246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Fractionated Stem Cell Infusions
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2015 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Not applicable Interventional Results available

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

NCT00789256
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Interventions
Melphalan, Bortezomib, Melphalan and bortezomib
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Jacksonville, Florida • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated No phase listed Observational

Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan

NCT00602147
View directory record Official record
Conditions
Mucositis, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

NCT00574509
View directory record Official record
Conditions
Lymphoma
Interventions
131Iodine-Anti-B1 Radioimmunotherapy, BEAM
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

NCT00577278
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma
Interventions
rituximab, fludarabine phosphate, melphalan, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, laboratory biomarker analysis
Biological · Drug · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

NCT00002810
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Temple University
Other
Eligibility
16 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2010 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

Therapy for Children With Neuroblastoma

NCT00135135
View directory record Official record
Conditions
Neuroblastoma
Interventions
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid, Radiation therapy, Surgery, Peripheral Stem cell transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 2, 2008 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated Phase 1 Interventional

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

NCT02116959
View directory record Official record
Conditions
Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Interventions
Melphalan, Carboplatin, Etoposide, Vincristine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 3 Interventional

Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies

NCT00275678
View directory record Official record
Conditions
Blood Stem Cell Transplant
Interventions
Blood stem cell versus bone marrow transplant
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 66 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Sep 14, 2026, 7:03 PM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated Phase 1 Interventional Results available

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma

NCT02043860
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Total Marrow Irradiation, Autologous Transplant, Melphalan, Filgrastim (G-CSF)
Radiation · Procedure · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

NCT00003353
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Scottsdale, Arizona • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional Results available

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

NCT01548573
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 14, 2026, 7:03 PM EDT
Recruiting Phase 2 Interventional

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation
Drug · Procedure · Biological + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, stem cell, Dexamethasone, Clarithromycin
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
10
States / cities
Basking Ridge, New Jersey • New Brunswick, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

NCT00743288
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Panobinostat
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated Phase 3 Interventional Results available

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

NCT00573391
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, and Dexamethasone, Velcade, Melphalan, and Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 14, 2026, 7:03 PM EDT
Recruiting Phase 2 Interventional

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

NCT04332874
View directory record Official record
Conditions
Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Interventions
Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

NCT00890500
View directory record Official record
Conditions
Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Interventions
Fludarabine, Melphalan, Antithymocyte Globulin, Sirolimus, Tacrolimus
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 14, 2026, 7:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and High-Dose Melphalan

NCT01079936
View directory record Official record
Conditions
Myeloma, Stem Cell Transplantation
Interventions
Lenalidomide, Melphalan, Stem Cell Infusion
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional Results available

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

NCT00505921
View directory record Official record
Conditions
Lymphoma
Interventions
Campath-1H, G-CSF, GM-CSF, BCNU, Stem Cell Transplant, Preparative Regimen for Allogenic Stem Cell Transplantation, Cytarabine, Etoposide, Melphalan, Campath, Fludarabine, Cyclophosphamide, Low dose total body irradiation
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 14, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional Results available

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

NCT03615144
View directory record Official record
Conditions
Non-Malignant Hematologic Disorders
Interventions
Melphalan, Thiotepa, Clofarabine, Fludarabine, Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®), CliniMACS reagents
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 14, 2026, 7:03 PM EDT